Back to Search
Start Over
The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis
- Source :
- Seminars in Neurology. 33:013-025
- Publication Year :
- 2013
- Publisher :
- Georg Thieme Verlag KG, 2013.
-
Abstract
- The modern era of the therapy for multiple sclerosis began in the 1990s with introduction of interferon beta and glatiramer acetate. Now 20 years since the introduction of these disease modifying therapies, several alternatives have become available. Although, in many cases, these new agents seem especially effective, there is little head-to-head trial data to actually compare the efficacy of the newer agents to that of the older. Moreover, there is no doubt that these older agents are both effective and very safe - something which has not always proven true about the newer therapies. Consequently, there will continue to be a place for these injectable treatments, even as we move into an era where physicians are confronted with many treatment possibilities.
- Subjects :
- medicine.medical_specialty
Multiple Sclerosis
Treatment outcome
MEDLINE
Alternative medicine
Disease
Adjuvants, Immunologic
medicine
Animals
Humans
Immunologic Factors
Glatiramer acetate
Intensive care medicine
Interferon beta
business.industry
Multiple sclerosis
Glatiramer Acetate
Interferon-beta
medicine.disease
Treatment Outcome
Neurology
Immunology
Neurology (clinical)
Peptides
business
medicine.drug
Subjects
Details
- ISSN :
- 10989021 and 02718235
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Seminars in Neurology
- Accession number :
- edsair.doi.dedup.....80509ac89a7eed03d28b6c2331881ab9
- Full Text :
- https://doi.org/10.1055/s-0033-1343792